Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ARIAD Pharmaceuticals has received a US patent which covers composition-of-matter patent protection for ponatinib, a pan-BCR-ABL inhibitor, through 22 December 2026.
Subscribe to our email newsletter
The patent number 8,114,874 was entitled, Substituted Acetylenic Imidazo[1,2-B] Pyridazine Compounds as Kinase Inhibitors.
The new patent covers both the compound itself and its pharmaceutical compositions.
Additional patent applications covering ponatinib in the US and in other countries are pending, the company said.
ARIAD chairman and CEO Harvey Berger said they are preparing to file for US and European MAAs for use of ponatinib in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia patients.